General description
We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1L10 is a ZooMAb® recombinant rabbit monoclonal antibody that specifically detects VCP. It targets an epitope within 25 amino acids from the C-terminal half.
Immunogen
KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal half of human VCP.
Application
Quality Control Testing
Evaluated by Western Blotting in Raji cell lysate.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected VCP in Raji cell lysate.
Tested Applications
Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected VCP in lysates from A-431 cells, C6 cells and mouse brain tissue.
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected VCP in NIH/3T3 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected VCP in human cerebral cortex tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Transitional endoplasmic reticulum ATPase (UniProt: P55072; also known as TER ATPase, EC:3.6.4.6, 15S Mg(2+)-ATPase p97 subunit, Valosin-containing protein, VCP) is encoded by the VCP (also known as HEL-220, HEL-S-70 ) gene (Gene ID: 7415) in human. VCP is a homohexameric protein that forms a ring-shaped particle and displays a six-fold radial symmetry. It is shown to be essential for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. It is involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles, which derive from part-rough, part-smooth transitional elements of tER. Vesicle budding from the tER is reported to be an ATP-dependent process. It is shown that the ternary complex containing UFD1, VCP and NPLOC4 regulates spindle disassembly at the end of mitosis. This complex binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. VCP is also involved in DNA damage response. It is recruited to double-strand breaks sites in a RNF8- and RNF168-dependent manner and promotes the recruitment of TP53BP1 at DNA damage sites. It is recruited to stalled replication forks by DNA-binding metalloprotease SPRTN and together they are involved in the repair of covalent DNA-protein cross-links during DNA synthesis. VCP is also required for cytoplasmic retro-translocation of stressed/damaged mitochondrial outer-membrane proteins and their subsequent proteasomal degradation. DNA damage is reported to induce phosphorylation of serine 784 that selectively enhances chromatin-associated protein degradation and is required for DNA repair, signaling, and cell survival. The functional effects of serine 784 phosphorylation correlate with a decrease in VCP association with chromatin, cofactors NPL4/UFD1, and polyubiquitinated substrates. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: (Ref.: Zhu, C., et al.(2020). Cell Rep. 31(10); 107745; Fielden, J., et al. (2020). Nat. Commun. 11(1); 1274).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.